ACCC President Highlights Oncology Community Response to COVID-19 Pandemic
Randall A. Oyer, MD, discusses the importance of the ACCC community during the unprecedented coronavirus disease 2019 pandemic.
Related Articles
Lessons Learned from REACH-3 Clinical Trial
Yi-Bin Chen, MD, presents the results of the phase-3 randomized REACH-3 Trial, highlighting the superior best overall response rate of 75% in the experimental arm…
Lenvatinib Is Effective, Regardless of Age in HCC
No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.
Behind the CheckMate-77T Trial of a Nivolumab-Based Regimen in NSCLC
Tina Cascone, MD, PhD, discusses the CheckMate-77T trial of perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab for the treatment…
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients…
Legislative Changes and Their Impact on Community Oncology Care
In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.
GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.
Tislelizumab Plus Chemotherapy Improves Survival in Small Cell Lung Cancer
Adding tislelizumab to chemotherapy improved overall survival and progression-free survival in patients with extensive-stage small cell lung cancer, according to findings from a phase 3…
Understanding the Role of Zanubrutinib for the Treatment of CLL
Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.
Setting Expectations + First-Line and Second-Line Treatment of Graft Versus Host Disease
A medical professional outlines the goals and challenges of communicating with his patient, emphasizing the importance of setting realistic expectations for halting disease progression and…
How the PERSIST-2 Results Show The Benefit of Pacritinib in MF
During a Case-Based Roundtable® event, John Mascarenhas, MD, discussed the efficacy data behind the use of pacritinib in patients with myelofibrosis in the first article…